Wu and colleagues developed a new lipid nanodrug for post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, which lack effective therapy except lung transplantation. This new lipid nanodrug enabled lung-targeted delivery of RNA therapeutics (anti-microRNA-21) and showed strong anti-fibrotic effects, representing a potent treatment for pulmonary fibrosis.
All Keywords
【저자키워드】 COVID-19, pulmonary fibrosis, microRNA, liposomes, drug delivery, MT: Oligonucleotides: Therapies and Applications, miR-21,
【저자키워드】 COVID-19, pulmonary fibrosis, microRNA, liposomes, drug delivery, MT: Oligonucleotides: Therapies and Applications, miR-21,